vs
STANDARD BIOTOOLS INC.（LAB）与SYPRIS SOLUTIONS INC（SYPR）财务数据对比。点击上方公司名可切换其他公司
SYPRIS SOLUTIONS INC的季度营收约是STANDARD BIOTOOLS INC.的1.5倍（$30.3M vs $19.6M），SYPRIS SOLUTIONS INC净利率更高（-12.9% vs -177.4%，领先164.5%），SYPRIS SOLUTIONS INC同比增速更快（-9.5% vs -11.5%），SYPRIS SOLUTIONS INC自由现金流更多（$-1.5M vs $-23.1M），过去两年SYPRIS SOLUTIONS INC的营收复合增速更高（-7.7% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
SYPRIS SOLUTIONS INC是美国的工程制造服务商，面向航空航天、国防、汽车、商用工业领域，提供定制化制造、性能测试及增值工程支持服务，满足全球企业客户关键任务系统及部件的相关需求。
LAB vs SYPR — 直观对比
营收规模更大
SYPR
是对方的1.5倍
$19.6M
营收增速更快
SYPR
高出2.0%
-11.5%
净利率更高
SYPR
高出164.5%
-177.4%
自由现金流更多
SYPR
多$21.6M
$-23.1M
两年增速更快
SYPR
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $30.3M |
| 净利润 | $-34.7M | $-3.9M |
| 毛利率 | 48.5% | 4.6% |
| 营业利润率 | -168.5% | -10.9% |
| 净利率 | -177.4% | -12.9% |
| 营收同比 | -11.5% | -9.5% |
| 净利润同比 | -28.8% | -2992.6% |
| 每股收益（稀释后） | $-0.09 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSYPR
| Q4 25 | — | $30.3M | ||
| Q3 25 | $19.6M | $28.7M | ||
| Q2 25 | $21.8M | $31.4M | ||
| Q1 25 | $40.8M | $29.5M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | $22.1M | $35.7M | ||
| Q2 24 | $22.5M | $35.5M | ||
| Q1 24 | $45.5M | $35.6M |
净利润LABSYPR
| Q4 25 | — | $-3.9M | ||
| Q3 25 | $-34.7M | $517.0K | ||
| Q2 25 | $-33.5M | $-2.1M | ||
| Q1 25 | $-26.0M | $-899.0K | ||
| Q4 24 | — | $135.0K | ||
| Q3 24 | $-26.9M | $390.0K | ||
| Q2 24 | $-45.7M | $16.0K | ||
| Q1 24 | $-32.2M | $-2.2M |
毛利率LABSYPR
| Q4 25 | — | 4.6% | ||
| Q3 25 | 48.5% | 7.2% | ||
| Q2 25 | 48.8% | 8.2% | ||
| Q1 25 | 48.4% | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | 54.9% | 16.8% | ||
| Q2 24 | 46.1% | 15.9% | ||
| Q1 24 | 53.1% | 8.1% |
营业利润率LABSYPR
| Q4 25 | — | -10.9% | ||
| Q3 25 | -168.5% | -6.1% | ||
| Q2 25 | -118.1% | -4.6% | ||
| Q1 25 | -80.8% | -0.4% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | -120.9% | 4.8% | ||
| Q2 24 | -134.5% | 3.6% | ||
| Q1 24 | -132.2% | -3.9% |
净利率LABSYPR
| Q4 25 | — | -12.9% | ||
| Q3 25 | -177.4% | 1.8% | ||
| Q2 25 | -153.7% | -6.5% | ||
| Q1 25 | -63.8% | -3.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -122.0% | 1.1% | ||
| Q2 24 | -203.3% | 0.0% | ||
| Q1 24 | -70.6% | -6.2% |
每股收益（稀释后）LABSYPR
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $-0.09 | $0.02 | ||
| Q2 25 | $-0.09 | $-0.09 | ||
| Q1 25 | $-0.07 | $-0.04 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.07 | $0.02 | ||
| Q2 24 | $-0.12 | $0.00 | ||
| Q1 24 | $-0.27 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $17.8M |
| 总资产 | $539.6M | $107.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSYPR
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABSYPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSYPR
| Q4 25 | — | $17.8M | ||
| Q3 25 | $399.7M | $20.0M | ||
| Q2 25 | $424.5M | $18.7M | ||
| Q1 25 | $454.6M | $19.0M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $489.3M | $18.2M | ||
| Q2 24 | $510.3M | $19.0M | ||
| Q1 24 | $577.3M | $20.8M |
总资产LABSYPR
| Q4 25 | — | $107.8M | ||
| Q3 25 | $539.6M | $112.5M | ||
| Q2 25 | $557.0M | $105.8M | ||
| Q1 25 | $579.6M | $110.2M | ||
| Q4 24 | — | $119.4M | ||
| Q3 24 | $681.5M | $121.6M | ||
| Q2 24 | $708.7M | $124.2M | ||
| Q1 24 | $777.7M | $129.0M |
负债/权益比LABSYPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-1.5M |
| 自由现金流率自由现金流/营收 | -118.1% | -5.0% |
| 资本支出强度资本支出/营收 | 4.5% | 1.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-6.5M |
8季度趋势，按日历期对齐
经营现金流LABSYPR
| Q4 25 | — | $-1.1M | ||
| Q3 25 | $-22.2M | $-178.0K | ||
| Q2 25 | $-20.7M | $1.1M | ||
| Q1 25 | $-30.3M | $-5.5M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-27.9M | $-4.8M | ||
| Q2 24 | $-39.0M | $6.2M | ||
| Q1 24 | $-62.5M | $-1.7M |
自由现金流LABSYPR
| Q4 25 | — | $-1.5M | ||
| Q3 25 | $-23.1M | $-390.0K | ||
| Q2 25 | $-22.6M | $941.0K | ||
| Q1 25 | $-35.3M | $-5.5M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-30.1M | $-4.9M | ||
| Q2 24 | $-41.0M | $6.0M | ||
| Q1 24 | $-63.3M | $-2.0M |
自由现金流率LABSYPR
| Q4 25 | — | -5.0% | ||
| Q3 25 | -118.1% | -1.4% | ||
| Q2 25 | -103.6% | 3.0% | ||
| Q1 25 | -86.6% | -18.8% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -136.4% | -13.8% | ||
| Q2 24 | -182.2% | 16.8% | ||
| Q1 24 | -138.9% | -5.7% |
资本支出强度LABSYPR
| Q4 25 | — | 1.3% | ||
| Q3 25 | 4.5% | 0.7% | ||
| Q2 25 | 8.7% | 0.5% | ||
| Q1 25 | 12.4% | 0.0% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | 10.2% | 0.4% | ||
| Q2 24 | 8.6% | 0.5% | ||
| Q1 24 | 1.7% | 0.9% |
现金转化率LABSYPR
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
